Trends in Cancer

Papers
(The H4-Index of Trends in Cancer is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Subscription & copyright page317
FBXW10: a male-biased E3 ligase in liver cancer193
Engineering growth factor ligands and receptors for therapeutic innovation183
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis180
Spliced to kill: RNA mis-splicing derived cancer neoantigens171
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology165
Platelets: tailoring metastasis treatment153
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy150
Revumenib: a new era in acute leukemia treatment138
Tumor-resident microbes: the new kids on the microenvironment block137
Advisory Board and Contents136
Subscription & copyright page135
Navigating life as an early career researcher128
Subscription and copyright page128
Onco-condensates: formation, multi-component organization, and biological functions127
Engine shutdown: migrastatic strategies and prevention of metastases124
Accessing the vasculature in cancer: revising an old hallmark119
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer116
Radiotherapy and immunotherapy: open questions and future strategies115
Leveraging circulating microbial DNA for early cancer detection113
Subscription & copyright page104
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers90
GOT2 consider the tumor microenvironment81
Advisory Board and Contents80
Chromatin as an old and new anticancer target75
Oncogenic competence: balancing mutations, cellular state, and microenvironment75
Tumor immunology CRISPR screening: present, past, and future74
Gut microbiota – a double-edged sword in cancer immunotherapy73
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?73
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology73
Recent developments in myeloid immune modulation in cancer therapy70
Benefits and opportunities of the transgenic Oncopig cancer model68
Chromosomal instability and aneuploidy as causes of cancer drug resistance67
Regulation of metastatic organotropism65
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers64
Diet, nutrient supply, and tumor immune responses63
Pannexin biology and emerging linkages to cancer63
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis63
Crosstalk of T cells within the ovarian cancer microenvironment62
Cell death, therapeutics, and the immune response in cancer60
Advancements in combining targeted therapy and immunotherapy for colorectal cancer60
Subscription & copyright page57
Subscription & copyright page56
Advisory Board and Contents56
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation55
Cancer catecholamine conundrum55
Advisory Board and Contents55
Genetic immune escape in cancer: timing and implications for treatment55
Palmitate paves the way to lung metastasis52
Scaling data toward pan-cancer foundation models50
0.046987056732178